These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33995090)

  • 1. Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy.
    Ren C; Sun K; Zhang Y; Hu Y; Hu B; Zhao J; He Z; Ding R; Wang W; Liang C
    Front Pharmacol; 2021; 12():664181. PubMed ID: 33995090
    [No Abstract]   [Full Text] [Related]  

  • 2. Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway.
    Yang Y; Li N; Chen T; Zhang C; Liu L; Qi Y; Bu P
    Pharm Biol; 2019 Dec; 57(1):625-631. PubMed ID: 31545912
    [No Abstract]   [Full Text] [Related]  

  • 3. Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway.
    Mattii L; Moscato S; Ippolito C; Polizzi E; Novo G; Zucchi R; De Caterina R; Ghelardoni S; Madonna R
    Biomed Pharmacother; 2024 Sep; 178():117278. PubMed ID: 39116784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells.
    Song MW; Cui W; Lee CG; Cui R; Son YH; Kim YH; Kim Y; Kim HJ; Choi SE; Kang Y; Kim TH; Jeon JY; Lee KW
    Front Pharmacol; 2023; 14():1228646. PubMed ID: 38116084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy.
    Madonna R; Moscato S; Cufaro MC; Pieragostino D; Mattii L; Del Boccio P; Ghelardoni S; Zucchi R; De Caterina R
    Cardiovasc Res; 2023 May; 119(5):1175-1189. PubMed ID: 36627733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice.
    Sun X; Han F; Lu Q; Li X; Ren D; Zhang J; Han Y; Xiang YK; Li J
    Diabetes; 2020 Jun; 69(6):1292-1305. PubMed ID: 32234722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin].
    Rao H; Cheng W; Yu J; An X; Deng H; Zhang Z; Wu F; Ji F; Li S
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1146-1153. PubMed ID: 38162062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling.
    Abdelkader NF; Elbaset MA; Moustafa PE; Ibrahim SM
    Arch Pharm Res; 2022 Jul; 45(7):475-493. PubMed ID: 35767208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation.
    Luo Y; Ye T; Tian H; Song H; Kan C; Han F; Hou N; Sun X; Zhang J
    Lipids Health Dis; 2024 Sep; 23(1):308. PubMed ID: 39334359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S; Wang Q; Bakker D; Hu X; Zhang L; van der Made I; Tebbens AM; Kovácsházi C; Giricz Z; Brenner GB; Ferdinandy P; Schaart G; Gemmink A; Hesselink MKC; Rivaud MR; Pieper MP; Hollmann MW; Weber NC; Balligand JL; Creemers EE; Coronel R; Zuurbier CJ
    Basic Res Cardiol; 2024 Oct; 119(5):751-772. PubMed ID: 39046464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
    Mozolevska V; Schwartz A; Cheung D; Goyal V; Shaikh B; Dingman B; Kim E; Mittal I; Asselin CY; Edel A; Ravandi A; Thliveris J; Singal PK; Czaykowski P; Jassal DS
    Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H446-H458. PubMed ID: 30499710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure.
    Li X; Flynn ER; do Carmo JM; Wang Z; da Silva AA; Mouton AJ; Omoto ACM; Hall ME; Hall JE
    Front Cardiovasc Med; 2022; 9():859253. PubMed ID: 35647080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo.
    Li C; Zou R; Zhang H; Wang Y; Qiu B; Qiu S; Wang W; Xu Y
    Arch Toxicol; 2019 Jun; 93(6):1697-1712. PubMed ID: 31025080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.
    Oh CM; Cho S; Jang JY; Kim H; Chun S; Choi M; Park S; Ko YG
    Korean Circ J; 2019 Dec; 49(12):1183-1195. PubMed ID: 31456369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
    Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
    Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
    Jiang K; Xu Y; Wang D; Chen F; Tu Z; Qian J; Xu S; Xu Y; Hwa J; Li J; Shang H; Xiang Y
    Protein Cell; 2022 May; 13(5):336-359. PubMed ID: 33417139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy.
    El-Horany HE; Atef MM; Abdel Ghafar MT; Fouda MH; Nasef NA; Hegab II; Helal DS; Elseady W; Hafez YM; Hagag RY; Seleem MA; Saleh MM; Radwan DA; Abd El-Lateef AE; Abd-Ellatif RN
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
    Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.